摘要
目的观察国产重组链激酶在急性心肌梗塞治疗中的溶栓效果和不良反应。方法自１９９７年３月～１９９８年３月间对４７７例急性心肌梗塞患者予１５０万单位重组链激酶溶栓治疗，观察溶栓再通率、急性期死亡率、并发症以及不良反应发生率。结果溶栓再通率为８０２％，３５天死亡率５０％。不良反应中：过敏反应５５％（２６例），低血压７８％（３７例），出血１５１％（７２例），１例发生颅内出血但未致残，肝功能损害１４％（７例），半月后均恢复。结论国产重组链激酶为治疗急性心肌梗塞有效、安全的溶栓药物。
Objective To observe the clinical efficacy and safety of
intravenous thrombolytic therapy using domestic recombinant streptokinase (rSK) in acute
myocardial infarction (AMI) Methods Four hundred and seventy seven patients, admitted to the
multicenter clinical trial group during March 1997 to March 1998, were treated by intravenous
rSK (15MU) The patency of infarctrelated coronary artery was assessed by unified clinical
criteria Adverse reactions were also observed Results The patency was 802%, 35day mortality
was 5% The rate of allergic reaction was 55% The rate of hypotension was 78%, of bleeding was
151% (including 1 case of nonfatal intracranial hemorrhage) The rate of liver function damage
was 15%, and all recovered in half a month Conclusion Domestic recombinant streptokinase is
an effective, reliable and safe thrombolytic agent
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
1999年第3期180-183,共4页
Chinese Journal of Cardiology
关键词
心肌梗塞
重组链激酶
AMI
药物疗法
myocardial infarctionrecombinant
streptokinasethrombolytic therapy
